Adagene vs Crescent Biopharma
ADAG and CBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADAG and CBIO compare
Adagene keeps more of each dollar of sales as profit, with a net margin of −230% compared with −728% at Crescent Biopharma.
Crescent Biopharma scores higher on the StockData Score (10 against 5 for Adagene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADAG | CBIO |
|---|---|---|
| Size and price | ||
| Market cap | – | $534M |
| Share price | $2.00 | $14.37 |
| Change, 1 year | 17.6% | 8.5% |
| Change, 5 years | −79.5% | −92.4% |
| Beta (5Y) | 0.75 | 1.63 |
| Employees | 128 | 44 |
| StockData Score | ||
| Total score | 5 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 35.6× |
| P/B | – | 1.9× |
| FCF yield | – | −15.4% |
| Growth | ||
| Revenue growth (TTM) | 7333% | – |
| Revenue growth, 5Y average | 61.4% (better) | 1.3% |
| Profitability | ||
| Operating margin | −279% (better) | −1217% |
| Net margin | −230% (better) | −728% |
| FCF margin | −204% (better) | −550% |
| Return on equity | −27.7% (better) | −55.8% |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.00 |
| Interest coverage | −46.3× | – |
| Current ratio | 5.02 | 12.57 (better) |
| Altman Z-score | – | 10.62 |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 32.5% | 79.7% |
| Held by insiders | 16.8% | 38.6% |
| Insider net buying, 12 months | $162K | $29.1M (better) |
| Short interest, % of float | – | 18.3% |
Go deeper
- ADAG stock overview
- ADAG income statement
- ADAG valuation and score
- CBIO stock overview
- CBIO income statement
- CBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.